RxDoctor Payments Data

Helen Ahn, MD

Urology · Schaumburg, ILNPI 1952373037

Payments from drug & device makers

$647in general payments, 2019–2025

Across 30 payments — averaging $21.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Progenics Pharmaceuticals, Inc.$124
  • Coloplast$123
  • Astellas Pharma US Inc$81
  • Johnson & Johnson$65
  • AbbVie$53
  • 180 Medical, Inc.$40
  • plus $160 from 8 others

What the payments were for

  • Food & beverage$59291%
  • Education$559%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Progenics Pharmaceuticals, Inc.1$124
Coloplast6$123
Astellas Pharma US Inc3$81
Johnson & Johnson4$65
AbbVie(2 entities)4$53
180 Medical, Inc.2$40
Neotract Inc.2$34
Pfizer2$31
Travere Therapeutics, Inc.1$23
Bayer1$19
Hologic Sales And Service, LLC1$17
Mission Pharmacal Company1$14
Axonics, Inc.1$12
Healthtronics Stone Solutions, LLC1$8

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$647 in reported general payments places this provider in the 30th percentile of 550 urology providers in Illinois.

See all urology providers in Illinois

Medicare billing

Part B allowed, 2024
$160,533
Medicare patients
323
Services billed
1,714

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron59$43,618
GemtesaVibegron21$24,772
Trimethoprim35$2,293
Estradiol34$2,212
Tamsulosin Hcl124$1,742
Solifenacin Succinate41$1,225
Oxybutynin Chloride ErOxybutynin Chloride44$983
Methenamine Hippurate17$724
Finasteride35$607
Cephalexin75$576
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst50$508
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim68$249
Ciprofloxacin Hcl45$215
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen19$137

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$81$43,61859 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 550 urology providers in Illinois.

Other urology in Schaumburg

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →